SAGE news, real time SAGE stock news, SAGE news today

News

0.00%

The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14)

Benzinga · 5h ago

The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 13)

Benzinga · 1d ago

Sage Therapeutic Set to Possibly Pullback After Yesterday's Rally of 2.99%

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $93.90 to a high of $97.33. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $95.00 on volume of 294,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Comtex SmarTrend(R) · 2d ago

The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12)

Benzinga · 2d ago

Biogen discloses 10.7% stake in Sage Therapeutics

Biogen (BIIB) reports 10.7% stake in Sage Therapeutics (SAGE), representing 6.24M shares.In November 2020, both the companies teamed up to develop therapies in depression.

Seekingalpha · 3d ago

The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 7)

Benzinga · 01/08 12:25

Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference

--Company committed to accelerating pipeline and expanding product engine with goal of delivering at least two IND-enabling product candidates per year by 2023

BusinessWire · 01/07 08:30

Largest global study of 'long Covid' finds many patients unable to return to work six months later

Recent studies have shown a growing number of patients with Covid-19 experience persistent symptoms.

CNBC.com · 01/05 23:49

Benzinga's Top Upgrades, Downgrades For January 4, 2021

Upgrades * B of A Securities upgraded the previous rating for Expedia Group Inc (NASDAQ:EXPE) from Neutral to Buy. For the third quarter, Expedia Group had an EPS of $0.24, compared to year-ago quarter EPS of $3.37. At the moment, the stock has a 52-week...

Benzinga · 01/04 15:04

RBC Capital Downgrades Sage Therapeutics to Sector Perform, Raises Price Target to $86

RBC Capital analyst Brian Abrahams downgrades Sage Therapeutics (NASDAQ:SAGE) from Outperform to Sector Perform and raises the price target from $83 to $86.

Benzinga · 01/04 13:43

The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)

Benzinga · 12/29/2020 13:09

The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)

Benzinga · 12/23/2020 13:29

Sage Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. ET.

Business Wire · 12/23/2020 11:30

Sage Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

BusinessWire · 12/23/2020 08:30

Watch for Sage Therapeutic to Potentially Pullback After Gaining 2.21% Yesterday

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $84.14 to a high of $85.86. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $84.79 on volume of 294,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Comtex SmarTrend(R) · 12/22/2020 17:53

Is SAGE A Good Stock To Buy According To Hedge Funds?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 817 13F filings submitted by hedge funds and prominent investors. These filings show these funds’ portfolio positions as of September 30th, 2020. […]

Insider Monkey · 12/22/2020 14:39

Industry Analysts Just Upgraded Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Forecasts By 23%

Sage Therapeutics, Inc. ( NASDAQ:SAGE ) shareholders will have a reason to smile today, with the analysts making...

Simply Wall St. · 12/20/2020 09:00

After Yesterday's Rally of 2.87% Shares Could Potentially Pullback

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $73.10 to a high of $75.50. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $73.32 on volume of 294,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Comtex SmarTrend(R) · 12/16/2020 17:40

Sage Therapeutics names new chief executive

Sage Therapeutics (SAGE) has appointed Barry Greene new CEO of the company bringing more than 30 years of experience, who most recently served as president of Alnylam Pharmaceuticals.Barry joined the Sage Board of Directors

Seekingalpha · 12/16/2020 12:49

The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 15)

Benzinga · 12/16/2020 12:15

Webull provides a variety of real-time SAGE stock news. You can receive the latest news about SAGE through multiple platforms. This information may help you make smarter investment decisions.

About SAGE

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.